Boehringer Ingelheim, Gubra Enter Third Obesity Deal
New pact builds on duo’s R&D activities begun in 2017
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
You may also be interested in...
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
The German group has signed a second deal with Gubra to develop poly-agonist peptides for obesity that could be worth up to €240m.
Russian sovereign wealth fund and Sputnik V vaccine producer RDIF has teamed up with the country’s biggest bank to fund ‘home-grown’ tech and science-intensive start-ups.